Epi-on and epi-off describe how a cross-linking protocol handles the cornea's surface layer. The names alone do not tell you whether a treatment fits your diagnosis, which drug and device are involved, or what result to expect. Ask for the exact protocol before comparing recommendations.

The cross-linking service explains the treatment pathway. This comparison is for someone reviewing a proposed protocol; the CXL timing guide addresses whether and when treatment should be considered.

What is the practical difference?

In an epi-off procedure, the surface epithelium is removed before the riboflavin and ultraviolet-light steps. In an epi-on procedure, that layer is retained. The protocol also specifies the drug, light delivery, and other treatment conditions. Keeping the surface on is not the only difference between systems.

Cross-linking is intended to address corneal weakening; it is not a promise of glasses-free vision. Ask separately how vision will be corrected afterward. A specialty contact-lens plan can remain relevant even when cross-linking is recommended.

Is epi-on FDA-approved now?

Yes, a specific epi-on treatment has an FDA-approved indication. The EPIOXA HD/EPIOXA prescribing information describes use for keratoconus in adults and children age 13 and older with the O2n System and Boost Goggles. Its protocol includes supplemental oxygen and specific corneal-thickness requirements.

That does not make every treatment advertised as epi-on FDA-approved. Nor does approval establish suitability for a particular eye. Ask the clinician to identify the exact system and whether your diagnosis falls within its indication. This article does not establish that Visionary offers EPIOXA or every protocol discussed.

What could change the recommendation?

Bring prior corneal scans, prescription history, and records of earlier refractive surgery. Ask which findings support treatment and which limit the proposed protocol. Age, diagnosis, measured corneal thickness, scarring, surface health, and relevant medical history belong in that discussion.

Keratoconus and corneal ectasia after refractive surgery should not be treated as interchangeable labels when interpreting an approval. A recommendation for one condition does not automatically establish that the same labeled protocol applies to the other. Request a clear explanation if an off-label approach is proposed.

How should you compare recovery and evidence?

Ask about discomfort, bandage-lens care, time away from work, warning symptoms, and follow-up for the specific treatment. Do not assume epi-on means no healing requirements: the EPIOXA label includes a bandage contact lens and reports adverse reactions.

Ask whether a claim about effectiveness comes from a direct comparison of the exact protocols or from separate studies. Evidence for an older epi-on technique should not be silently substituted for a different system. The useful comparison includes the clinician's reasons for selecting the protocol and how stability will be monitored.

What should be clear before booking?

Request the drug and device names, suitability findings, alternatives, complete estimate, and expected follow-up schedule. Verify availability and coverage rather than assuming an approval guarantees either. Do not postpone an advised review while searching for a preferred marketing term.

A cornea consultation can organize the records and explain the treatment decision. The goal is a suitable, understood protocol with continuing care, rather than choosing from the surface-layer label alone.